Eton Pharmaceuticals vs Niagen Bioscience
Niagen Bioscience is the larger business, with $129m of revenue in fiscal 2025 against $80.0m for Eton Pharmaceuticals (1.6 times as much). Eton Pharmaceuticals grew faster (104.9% against 29.9%). Niagen Bioscience kept more of each dollar of sales as profit: a net margin of 13.4% against -5.8%.
| Latest fiscal year | Eton PharmaceuticalsETON, 2025 | Niagen BioscienceNAGE, 2025 |
|---|---|---|
| Revenue | $80.0m | $129m |
| Revenue growth | 104.9% | 29.9% |
| Net income | −$4.6m | $17.4m |
| Operating margin | -1.1% | — |
| Net margin | -5.8% | 13.4% |
| Return on equity | -18.2% | 28.3% |
| Free cash flow | $10.2m | $13.5m |
| Cash | $25.9m | $64.8m |
| Total debt | $30.6m | $0 |
| Debt to equity | 116.8% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $251,000 |
| Employees | 44 | — |
| Market value | $1.44bn | $185m |
| Price vs our value range | Above our value range | Within our value range |
| Moat score | 35 (Weak) | 27 (Weak) |
| Insider trades, 12 months | 0 buys, 29 sales | 2 buys, 0 sales |